In the latest quarter, 4 analysts provided ratings for Y-mAbs Therapeutics (NASDAQ:YMAB), showcasing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 3 | 0 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 1 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 0 | 2 | 0 | 0 | 0 |
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $22.0, along with a high estimate of $23.00 and a low estimate of $20.00. This upward trend is apparent, with the current average reflecting a 1.52% increase from the previous average price target of $21.67.
Diving into Analyst Ratings: An In-Depth...
Login or create a forever free account to read this news
Sign up/Log in
